A Danish company is spending $145 million upfront for certain rights to the first-ever needle-free adrenaline nasal spray for severe allergic reactions, unlocking sales potential … ...
The eye giant Alcon has launched an unlikely legal battle, suing a cell therapy startup that it invested in and claiming its shareholder rights are being violated as Aurion Biotech ...
Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...
US regulators gave the green light to Autolus Therapeutics’ cell therapy for adult B-cell precursor acute lymphoblastic leukemia, or B-ALL, that has returned or is not responding to prior treatment ...
The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) manufacturer ...
Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in patients with a different but sometimes related inflammatory condition ...
Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...
In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...
Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects ...
Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his ...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback